Synthetic Chemical Biology Core

项目概要-核心C 合成化学生物学核心（SCB）成立于2016年7月，由中心合并为 疾病途径的分子分析（CMADP）分子探针核心与新建立的化学 传染病生物学（CBID）药物化学核心。SCB的合成能力将满足 两个COBRE中心的具体目标。SCB在第三阶段的使命是提供CMADP附属的 初级教师，以及其他研究人员在堪萨斯州，与新的分子探针， 用于体外或体内阐明特定途径的药理学工具。SCB还将致力于 实现第三阶段之后的自我可持续性。核心将提供专家设计和合成的小分子 和肽分子探针，重点是产生荧光和其他亲和标记 分子。SCB将与其他CMADP资助的核心设施协同运作，包括基因组 测序核心，以确定影响体内探针功能的基因，和KU纳米工厂， 来开发成像和化学分析的设备。这种整合旨在使教师能够使用 用化学生物学方法研究生物学问题。 SCB在第三阶段将解决的具体目标是：（1）提供使能的小分子， COBRE研究人员和其他客户的兴趣;（2）提供常规和专业肽的合成 （3）提供必要的外联、行政和财政支持，以管理上述活动; 在COBRE项目的背景下开展活动，并为更大的堪萨斯研究社区提供服务 (4)继续发展核心实验室用户的临界质量，使该设施成为一个自我维持的， 是堪萨斯州生物医学研究基础设施的一部分。

PROJECT SUMMARY – CORE C The Synthetic Chemical Biology Core (SCB) was established in July 2016 from the merger of the Center for Molecular Analysis of Disease Pathways (CMADP) Molecular Probes Core with the newly established Chemical Biology of Infectious Disease (CBID) Medicinal Chemistry Core. The synthetic capabilities of the SCB will fulfill the specific aims of both COBRE centers. The mission for the SCB in Phase 3 is to provide CMADP-affiliated junior faculty, as well as other investigators in the state of Kansas, with novel molecular probes as pharmacological tools for in vitro or in vivo elucidation of particular pathways. The SCB will also work towards achieving self-sustainability beyond Phase 3. The Core will offer expert design and synthesis of small molecule and peptide molecular probes, with an emphasis on the generation of fluorescent and other affinity tagged molecules. The SCB will function synergistically with other CMADP-funded Core facilities, including the Genome Sequencing Core, to identify genes that impact functions of probes in vivo, and the KU Nanofabrication Facility, to develop devices for imaging and chemical analysis. This integration is designed to empower faculty to use chemical biology approaches to investigate biological problems. The specific aims that will be addressed by the SCB in Phase 3 are: (1) Provide enabling small molecules of interest to COBRE investigators and other clients; (2) Provide synthesis of conventional and specialized peptides to investigators; (3) Provide outreach, administrative, and fiscal support necessary to manage the above activities both in the context of COBRE projects and to offer services to the larger Kansas research community (4) To continue developing a critical mass of core lab users so that the facility becomes a self-sustaining, integral part of the biomedical research infrastructure in the state of Kansas.